Data & Technology

The transition to AI and machine learning was well underway long before ChatGPT burst onto the marketplace; however, organizations were, and still are, constrained by data challenges.

The Silverpod MAX RE offers real-time shipment visibility, while also helping companies accomplish their sustainability goals.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, discusses the state of affairs surrounding the Drug Supply Chain Security Act, along with opportunities for improvement.

Making connections between different datasets is essential to developing impactful medicines and driving more personalized patient care.

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s general manager of biopharma, dives into efficiencies presented by at-home diagnostic tests.

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s general manager of biopharma, discusses findings of a new physician survey that the company conducted.

Why they are a game changer, and ways to a adapt to a new era of state privacy regulations.

Following the evaluation, the company will decide whether it wants to move forward with the IDMO’s automated, end-to-end, cell therapy manufacturing platform.

Webinar dives into the trends, technology, and market necessities that can help tackle these obstacles.

LogiPharma Europe captured many timely topics, including the importance of next-level approaches in aligning temperature-controlled transit and visibility.

The company's latest service provides risk and quality management for the pharma and healthcare sectors.

By marrying real-world evidence and AI, pharma stakeholders can identify new opportunities to tailor interventions in a way that is most impactful to patients—helping them overcome roadblocks in initiating and maintaining therapy.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Lung-I Cheng, PhD, VP, Head of Cell & Gene Therapy Service Line, Cencora, offers his thoughts on industry pain points and where he envisions the market progressing in terms of its technological capabilities.

These advancements continue to act as a key driver in helping to boost the security, efficiency, and innovation of global industries, include pharma.

Results from the CORE-001 clinical trial are expected to be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.

The decision comes after success during formulation testing with convincing stability data.

The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.

Company's annual Commercial Summit updates Veeva Vault CRM status, along with AI partnerships.

Panel discussion uncovers how to alter one’s digital know-how for use in temperature-controlled supply chain.

Masterclass session addresses looking beyond a dashboard by added capabilities with added value.

Results of the trial suggest that early intervention for intracerebral hemorrhage using parafascicular surgery were safe.

Companies striving for transformed and targeted growth are exploring strategies that include partnerships, artificial intelligence, increased efficiencies, and competitive intelligence.

The collaboration strengthens the capabilities of Tower’s advanced passive temperature-controlled containers.

Although AI has simplified various market access processes, this technology does also present its share of barriers, so what can be done to find a happy medium?

Although time has welcomed novel advances in the space, new challenges pertaining to data and the physical technology, along with visibility and sustainability, are emerging.

Why manufacturers should leverage technology to address low adherence rates.

Presentation offers insight on this aforementioned model that assists retail and specialty-lite brands.

Fireside chat uncovers ways to leverage this technology in order to boost medication adherence, engagement, and outcomes.

Under the group purchasing agreement, the serialization business will be the sole provider of DSCSA services for Premier’s 4,300-plus hospital and health system network.

The Asia-Pacific location is expected to provide serialization solutions for counterfeit medication entering the pharma supply chain.